Arrr, the FDA be givin’ a hearty "Aye!" to Sotorasib and Panitumumab fer mCRC, savvy? Avast, let’s celebrate!
2025-01-20
Arrr, in the grand CodeBreaK 300 adventure, sotorasib and panitumumab be swashbucklin’ their way to better booty, bestin’ the standard treatments with finer response rates and keepin' landlubbers at bay for longer! Hoist the sails, Medscape be shoutin’ the news!
Ahoy, mateys! Gather round and lend an ear to this here tale of treachery upon the high seas of medicine! In the grand voyage known as the CodeBreaK 300 trial, two brave compounds, sotorasib and panitumumab, sailed forth, cuttin' through the waves with better response rates than the sorry lot of standard treatments. Aye, they be makin' waves like a kraken in a ship's hold!